Journal
BLOOD CANCER DISCOVERY
Volume 3, Issue 3, Pages 181-193Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2643-3230.BCD-22-0013
Keywords
-
Categories
Funding
- Hope Foundation
- American Cancer Society
- [GL P30CA015704-45]
- [MAB P30CA014236]
- [CRF T32-CA236621]
- [P30-CA046592]
- [DPS P30-CA054174]
Ask authors/readers for more resources
Patients with B-lymphoid malignancies, especially those who have received recent anticancer therapy, are at a uniquely high risk of severe COVID-19.
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancerrelated deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non- recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our fi ndings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. SIGNIFICANCE: Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available